Cargando…
Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction
OBJECTIVE: To investigate the beneficial role of prebiotics on endothelial dysfunction, an early key marker of cardiovascular diseases, in an original mouse model linking steatosis and endothelial dysfunction. DESIGN: We examined the contribution of the gut microbiota to vascular dysfunction observe...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868295/ https://www.ncbi.nlm.nih.gov/pubmed/28377388 http://dx.doi.org/10.1136/gutjnl-2016-313316 |
_version_ | 1783309125903450112 |
---|---|
author | Catry, Emilie Bindels, Laure B Tailleux, Anne Lestavel, Sophie Neyrinck, Audrey M Goossens, Jean-François Lobysheva, Irina Plovier, Hubert Essaghir, Ahmed Demoulin, Jean-Baptiste Bouzin, Caroline Pachikian, Barbara D Cani, Patrice D Staels, Bart Dessy, Chantal Delzenne, Nathalie M |
author_facet | Catry, Emilie Bindels, Laure B Tailleux, Anne Lestavel, Sophie Neyrinck, Audrey M Goossens, Jean-François Lobysheva, Irina Plovier, Hubert Essaghir, Ahmed Demoulin, Jean-Baptiste Bouzin, Caroline Pachikian, Barbara D Cani, Patrice D Staels, Bart Dessy, Chantal Delzenne, Nathalie M |
author_sort | Catry, Emilie |
collection | PubMed |
description | OBJECTIVE: To investigate the beneficial role of prebiotics on endothelial dysfunction, an early key marker of cardiovascular diseases, in an original mouse model linking steatosis and endothelial dysfunction. DESIGN: We examined the contribution of the gut microbiota to vascular dysfunction observed in apolipoprotein E knockout (Apoe(−/−)) mice fed an n-3 polyunsaturated fatty acid (PUFA)-depleted diet for 12 weeks with or without inulin-type fructans (ITFs) supplementation for the last 15 days. Mesenteric and carotid arteries were isolated to evaluate endothelium-dependent relaxation ex vivo. Caecal microbiota composition (Illumina Sequencing of the 16S rRNA gene) and key pathways/mediators involved in the control of vascular function, including bile acid (BA) profiling, gut and liver key gene expression, nitric oxide and gut hormones production were also assessed. RESULTS: ITF supplementation totally reverses endothelial dysfunction in mesenteric and carotid arteries of n-3 PUFA-depleted Apoe(−/−) mice via activation of the nitric oxide (NO) synthase/NO pathway. Gut microbiota changes induced by prebiotic treatment consist in increased NO-producing bacteria, replenishment of abundance in Akkermansia and decreased abundance in bacterial taxa involved in secondary BA synthesis. Changes in gut and liver gene expression also occur upon ITFs suggesting increased glucagon-like peptide 1 production and BA turnover as drivers of endothelium function preservation. CONCLUSIONS: We demonstrate for the first time that ITF improve endothelial dysfunction, implicating a short-term adaptation of both gut microbiota and key gut peptides. If confirmed in humans, prebiotics could be proposed as a novel approach in the prevention of metabolic disorders-related cardiovascular diseases. |
format | Online Article Text |
id | pubmed-5868295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58682952018-03-27 Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction Catry, Emilie Bindels, Laure B Tailleux, Anne Lestavel, Sophie Neyrinck, Audrey M Goossens, Jean-François Lobysheva, Irina Plovier, Hubert Essaghir, Ahmed Demoulin, Jean-Baptiste Bouzin, Caroline Pachikian, Barbara D Cani, Patrice D Staels, Bart Dessy, Chantal Delzenne, Nathalie M Gut Gut Microbiota OBJECTIVE: To investigate the beneficial role of prebiotics on endothelial dysfunction, an early key marker of cardiovascular diseases, in an original mouse model linking steatosis and endothelial dysfunction. DESIGN: We examined the contribution of the gut microbiota to vascular dysfunction observed in apolipoprotein E knockout (Apoe(−/−)) mice fed an n-3 polyunsaturated fatty acid (PUFA)-depleted diet for 12 weeks with or without inulin-type fructans (ITFs) supplementation for the last 15 days. Mesenteric and carotid arteries were isolated to evaluate endothelium-dependent relaxation ex vivo. Caecal microbiota composition (Illumina Sequencing of the 16S rRNA gene) and key pathways/mediators involved in the control of vascular function, including bile acid (BA) profiling, gut and liver key gene expression, nitric oxide and gut hormones production were also assessed. RESULTS: ITF supplementation totally reverses endothelial dysfunction in mesenteric and carotid arteries of n-3 PUFA-depleted Apoe(−/−) mice via activation of the nitric oxide (NO) synthase/NO pathway. Gut microbiota changes induced by prebiotic treatment consist in increased NO-producing bacteria, replenishment of abundance in Akkermansia and decreased abundance in bacterial taxa involved in secondary BA synthesis. Changes in gut and liver gene expression also occur upon ITFs suggesting increased glucagon-like peptide 1 production and BA turnover as drivers of endothelium function preservation. CONCLUSIONS: We demonstrate for the first time that ITF improve endothelial dysfunction, implicating a short-term adaptation of both gut microbiota and key gut peptides. If confirmed in humans, prebiotics could be proposed as a novel approach in the prevention of metabolic disorders-related cardiovascular diseases. BMJ Publishing Group 2018-02 2017-04-04 /pmc/articles/PMC5868295/ /pubmed/28377388 http://dx.doi.org/10.1136/gutjnl-2016-313316 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Gut Microbiota Catry, Emilie Bindels, Laure B Tailleux, Anne Lestavel, Sophie Neyrinck, Audrey M Goossens, Jean-François Lobysheva, Irina Plovier, Hubert Essaghir, Ahmed Demoulin, Jean-Baptiste Bouzin, Caroline Pachikian, Barbara D Cani, Patrice D Staels, Bart Dessy, Chantal Delzenne, Nathalie M Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction |
title | Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction |
title_full | Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction |
title_fullStr | Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction |
title_full_unstemmed | Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction |
title_short | Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction |
title_sort | targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction |
topic | Gut Microbiota |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868295/ https://www.ncbi.nlm.nih.gov/pubmed/28377388 http://dx.doi.org/10.1136/gutjnl-2016-313316 |
work_keys_str_mv | AT catryemilie targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT bindelslaureb targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT tailleuxanne targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT lestavelsophie targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT neyrinckaudreym targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT goossensjeanfrancois targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT lobyshevairina targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT plovierhubert targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT essaghirahmed targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT demoulinjeanbaptiste targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT bouzincaroline targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT pachikianbarbarad targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT canipatriced targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT staelsbart targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT dessychantal targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction AT delzennenathaliem targetingthegutmicrobiotawithinulintypefructanspreclinicaldemonstrationofanovelapproachinthemanagementofendothelialdysfunction |